Security Snapshot

Ascendis Pharma A/S - Common Stock (ASND) Institutional Ownership

CUSIP: 04351P101

13F Institutional Holders and Ownership History from Q1 2015 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

265

Shares (Excl. Options)

54,713,252

Price

$228.73

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
-9,989,819
Value change
-$2,135,952,308
Number of holders
265
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
62,915,156
SEC-reported price per share
$244.48
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • ASND - Ascendis Pharma A/S - Common Stock is tracked under CUSIP 04351P101.
  • 265 institutions reported positions in Q1 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 304 to 265 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $13,781,007,160 to $12,503,369,311.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 265 institutions filings for Q1 2026.

Open SEC evidence

Security key

04351P101

Latest holder period

Q1 2026

13F holders

265

13D/G owners

6

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
ASND
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
T. Rowe Price Investment Management, Inc. 10% +114% $1,617,120,732 +$954,097,949 6,506,219 +144% T. Rowe Price Investment Management, Inc. 30 Apr 2026
WESTFIELD CAPITAL MANAGEMENT CO LP 8.5% -7.8% $1,115,183,925 -$73,663,872 5,185,696 -6.2% Westfield Capital Management Company, L.P. 31 Dec 2025
FMR LLC 6.6% -18% $957,439,699 -$197,557,979 3,852,101 -17% FMR LLC 31 Mar 2026
JANUS HENDERSON GROUP PLC 6% -22% $924,469,795 -$150,026,520 3,719,452 -14% JANUS HENDERSON GROUP PLC 31 Mar 2026
Artisan Partners Limited Partnership 5.2% $687,887,717 3,225,885 Artisan Partners Asset Management Inc. 31 Dec 2025
Capital International Investors 3.2% -40% $492,207,917 -$267,935,411 2,013,285 -35% Capital International Investors 31 Mar 2026

As of 31 Mar 2026, 265 institutional investors reported holding 54,713,252 shares of Ascendis Pharma A/S - Common Stock (ASND). This represents 87% of the company’s total 62,915,156 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
72%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 16% 10,281,496 0% 25% $2,351,686,580
Avoro Capital Advisors LLC 8% 5,062,500 -0.95% 11% $1,157,945,625
WESTFIELD CAPITAL MANAGEMENT CO LP 7.7% 4,813,440 -7.2% 4.6% $1,100,978,089
FMR LLC 6.2% 3,876,601 -6.7% 0.05% $886,694,943
Artisan Partners Limited Partnership 5.1% 3,230,188 +0.13% 1.2% $738,840,836
FRANKLIN RESOURCES INC 3.3% 2,051,948 +7.4% 0.11% $469,341,976
Capital International Investors 3.1% 1,958,843 -36% 0.11% $448,046,159
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 3% 1,860,669 -1.4% 0.15% $425,574,778
WELLINGTON MANAGEMENT GROUP LLP 2.8% 1,757,633 -0.29% 0.08% $402,023,397
PERCEPTIVE ADVISORS LLC 2.4% 1,531,421 +42% 6.9% $350,281,925
AMERICAN CENTURY COMPANIES INC 2.2% 1,397,119 -3.2% 0.16% $319,564,431
Capital World Investors 1.4% 900,517 0.03% $205,975,253
PRINCIPAL FINANCIAL GROUP INC 1.4% 896,397 -13% 0.11% $205,032,887
BlackRock, Inc. 1.1% 661,054 +5.2% 0% $151,202,889
Polar Capital Holdings Plc 1% 651,712 +76% 0.65% $149,066,086
MORGAN STANLEY 0.96% 606,348 -1.9% 0.01% $138,690,183
GOLDMAN SACHS GROUP INC 0.9% 566,192 -5.1% 0.02% $129,505,096
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 0.88% 556,427 +12% 0.22% $127,272,000
JPMORGAN CHASE & CO 0.86% 539,434 +6.3% 0.01% $117,785,480
AMERIPRISE FINANCIAL INC 0.76% 476,466 -13% 0.03% $108,982,068
FIL Ltd 0.71% 447,421 -6.5% 0.08% $102,338,605
Vestal Point Capital, LP 0.6% 375,000 +114% 2.4% $85,773,750
Spyglass Capital Management LLC 0.58% 367,972 -11% 6% $84,166,236
Invesco Ltd. 0.58% 362,109 -38% 0.01% $82,825,192
SEI INVESTMENTS CO 0.56% 351,146 +25% 0.07% $80,317,658

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
45
Latest
Q1 2026
Rows shown
1-25 of 45
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 54,713,252 $12,503,369,311 -$2,135,952,308 $228.73 265
2025 Q4 64,677,198 $13,781,007,160 +$36,599,194 $213.24 304
2025 Q3 63,798,487 $12,683,838,954 +$232,138,786 $198.81 279
2025 Q2 62,895,390 $10,855,906,781 -$373,773,069 $172.60 245
2025 Q1 65,180,066 $10,147,446,038 +$223,136,493 $155.86 241
2024 Q4 63,751,521 $8,776,308,689 +$115,863,512 $137.67 212
2024 Q3 62,595,716 $9,312,956,409 +$237,478,312 $149.31 218
2024 Q2 60,687,245 $8,276,478,215 -$25,623,552 $136.38 202
2024 Q1 60,791,422 $9,189,438,728 +$198,420,492 $151.17 188
2023 Q4 60,262,338 $7,590,188,894 -$95,295,592 $125.95 183
2023 Q3 60,279,508 $5,644,577,484 -$61,738,785 $93.64 157
2023 Q2 61,039,136 $5,447,708,812 -$42,606,636 $89.25 156
2023 Q1 60,982,797 $6,535,152,679 -$603,913,240 $107.22 160
2022 Q4 65,956,055 $8,054,269,679 -$66,421,048 $122.13 183
2022 Q3 66,716,414 $6,891,080,476 +$149,538,106 $103.26 177
2022 Q2 63,211,628 $5,875,622,934 +$99,259,708 $92.96 162
2022 Q1 61,928,932 $7,267,064,424 +$416,027,513 $117.36 169
2021 Q4 58,376,386 $7,851,336,290 -$60,447,865 $134.53 168
2021 Q3 58,008,737 $9,244,880,979 +$506,030,857 $159.39 162
2021 Q2 55,049,436 $7,239,726,130 +$277,622,452 $131.55 167
2021 Q1 52,687,197 $6,790,538,552 -$259,999,867 $128.88 172
2020 Q4 54,357,110 $9,065,494,890 +$123,538,090 $166.78 173
2020 Q3 53,548,292 $8,263,618,101 +$776,855,285 $154.32 150
2020 Q2 48,248,343 $7,132,005,530 +$39,025,561 $147.90 149
2020 Q1 47,871,754 $5,391,239,456 +$191,350,357 $112.61 143
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .